🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 123 of 151

  1. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Taxanes-induced peripheral neuropathy

    phase 2 small molecule active

    1 trial

  2. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Capecitabine-induced hand and foot syndrome

    phase 2 small molecule active

    1 trial

  3. TAR-0520 gel matching vehicle without active ingredients, TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    EGFR inhibitor-induced folliculitis

    phase 2 small molecule active

    1 trial

  4. TARA-002

    Protara Therapeutics

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    3 trials

  5. TARA-002

    Protara Therapeutics

    Lymphatic Malformation

    phase 2 mab active

    1 trial

  6. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  7. TAS-205

    Taiho Pharma Netherlands B.V.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  8. TAS-303

    Taiho Pharma Netherlands B.V.

    Stress Urinary Incontinence

    phase 2 small molecule completed

    1 trial

  9. TAVR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aortic Valve Disease

    phase 2 other active

    1 trial

  10. TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  11. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  12. TD-0903

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Associated With COVID-19

    phase 2 small molecule completed

    2 trials

  13. TD-1211

    Theravance Biopharma Ireland Umited

    Opioid-induced Constipation (OIC)

    phase 2 small molecule completed

    1 trial

  14. TD-1211

    Theravance Biopharma Ireland Umited

    Healthy

    phase 2 small molecule completed

    2 trials

  15. TD-1211

    Theravance Biopharma Ireland Umited

    Opioid Induced Constipation

    phase 2 small molecule completed

    2 trials

  16. TD-1792

    Theravance Biopharma Ireland Umited

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  17. TD-4208

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  18. TD-4208

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    2 trials

  19. TD-5108

    Theravance Biopharma Ireland Umited

    Chronic Constipation

    phase 2 small molecule completed

    1 trial

  20. TD-8236

    Theravance Biopharma Ireland Umited

    Asthma

    phase 2 small molecule completed

    2 trials

  21. TD-8954

    Takeda

    Enteral Feeding Intolerance

    phase 2 small molecule completed

    1 trial

  22. TD-9855

    Theravance Biopharma Ireland Umited

    Attention-Deficit/Hyperactivity Disorder

    phase 2 small molecule completed

    1 trial

  23. TD-9855

    Theravance Biopharma Ireland Umited

    Neurogenic Orthostatic Hypotension

    phase 2 small molecule completed

    1 trial

  24. TD-9855 Group 1

    Theravance Biopharma Ireland Umited

    Fibromyalgia

    phase 2 small molecule completed

    1 trial

  25. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  26. TDV

    Takeda

    Healthy

    phase 2 mab completed

    1 trial

  27. TDV Liquid Formulation 1

    Takeda

    Dengue Fever

    phase 2 small molecule completed

    1 trial

  28. TEBENTAFUSP

    Fondazione Telethon ETS

    metastatic uveal melanoma HLA A*02:01 positive

    phase 2 small molecule active

    1 trial

  29. TECLISTAMAB, TECLISTAMAB

    Fondazione Telethon ETS

    refractory/relapsed multiple myeloma

    phase 2 small molecule active

    1 trial

  30. TEDOPI, LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  31. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  32. TEMOZOLOMIDE

    The George Institute

    Diffuse low-grade gliomas

    phase 2 small molecule active

    1 trial

  33. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  34. TEMOZOLOMIDE VIATRIS 5 mg, gélule, Capivasertib, TEMOZOLOMIDE VIATRIS 100 mg, gélule, VINORELBINE ACCORD 20 mg, capsule molle, Votubia 3 mg dispersible tablets, Bavencio 20 mg/mL concentrate for solution for infusion, Peposertib, INC280, Enasidenib Mesilate, Futibatinib, TEMOZOLOMIDE VIATRIS 20 mg, gélule, Capivasertib, VINORELBINE ACCORD 30 mg, capsule molle, INC280, Enasidenib Mesilate, Votubia 5 mg dispersible tablets, Votubia 2 mg dispersible tablets, Capivasertib

    The George Institute

    pediatric cancer

    phase 2 small molecule active

    1 trial

  35. TEMOZOLOMIDE, TEMOZOLOMIDE, CAPECITABINE

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial

  36. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  37. TENOFOVIR ALAFENAMIDE , Sodium chloride solution 0.9%, ENTECAVIR , TENOFOVIR DISOPROXIL , JNJ-73763989

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  38. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial

  39. TERBINAFINE HYDROCHLORIDE (1%)

    United Therapeutics Europe Ltd

    Tinea Pedis

    phase 2 small molecule active

    1 trial

  40. TETRACOSACTIDE , EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

  41. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  42. TEV-48574

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule terminated

    1 trial

  43. TEV-48574

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  44. TEV-48574

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule completed

    1 trial

  45. TEV-48574 Dose Regimen A

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule active

    1 trial

  46. TEV-48574, Placebo IMP for sc infusion is provided as a liquid solution in the same formulation as TEV-48574, except for the absence of active protein.

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  47. TEV-53275 Dose A

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule terminated

    1 trial

  48. TEV-53408

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.